ECEESPE2025 ePoster Presentations Endocrine Related Cancer (100 abstracts)
1Regional University Military Hospital, Oran, Algeria; 2Military University Hospital Specialized in Orthopedic Surgery Rehabilitation and Orthoprosthetics, Algiers, Algeria
JOINT584
Introduction: Neuroendocrine tumours (NETs) are tumours that can occur throughout the body, generally affecting the digestive tract and lungs, and are characterised by their ability to secrete hormones. Rare tumours; their annual incidence is estimated at 2 to 5 new cases per 100,000 people per year, with the most affected age group being between 40 and 60. In this presentation, we report the case of a small cell lung cancer revealed by hepatalgia.
Observation: This 73-year-old patient, a 30-year smoking cessation, and type 2 diabetes mellitus on oral anti-diabetic, was admitted to our clinic for an etiological diagnosis of a NET objectified by abdominal MRI following 03 months of abdominal pain which revealed the presence of a suspicious hepatic nodule. Anapathological examination of a biopsy was consistent with a small cell NET hepatic metastasis. Immunohistochemistry was positive for anti-CgA antibodies, anti-Synaptophusin antibodies and 80% anti-Ki67 antibodies. A thoraco-abdominal CT scan revealed a pulmonary condensation systematised in the right middle lobe, with multiple secondary hepatic and mediastinal localisations. An octreoscan performed revealed a somatostatin receptor expressing lung neoplasia at the stage of lymph node and liver metastases. The patient had undergone bronchial fibroscopy with biopsy of the right middle and lower lobes, the results of which were in favour of a histopathological appearance and immunohistochemical profile of a small cell lung cancer.
Discussion-Conclusion: The NETs diversity of symptoms and their rarity present a major challenge for healthcare professionals. between the main types of lung cancer, 4 major histological types alone account for 95% of cases: [squamous cell carcinomas, adenocarcinomas, large cell carcinomas (classified as non-small cell carcinomas)], and small cell carcinomas. The therapeutic approach depends on the nature of the tumour, ranging from chemotherapy to specific management: targeted therapy.